Nature Medicine, Washington, DC, USA.
Nat Biotechnol. 2009 Nov;27(11):971-2. doi: 10.1038/nbt1109-971.
Steve Reed believes the organization he has founded has the potential to radically increase the developing world's access to vaccines for neglected diseases. The efforts of the Seattle-based Infectious Disease Research Institute (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 'swine' flu pandemic. IDRI developed an adjuvant to boost the effectiveness and supplies of flu vaccines and is making the technology available to vaccine manufacturers in developing nations. Charlotte Schubert talks to Reed about how IDRI, a 90-person operation with a $19 million annual budget, could have such a big impact.
史蒂夫·里德（Steve Reed）相信他所创立的组织有潜力从根本上增加发展中国家可获得的针对被忽视疾病的疫苗。总部位于西雅图的传染病研究所（IDRI）是一家非盈利性生物技术公司，该所的努力可能会在 H1N1“猪流感”大流行期间开始取得成效。IDRI 开发了一种佐剂来提高流感疫苗的效力和供应，并将这项技术提供给发展中国家的疫苗制造商。夏洛特·舒伯特（Charlotte Schubert）与里德（Reed）探讨了这家拥有 90 名员工和 1900 万美元年度预算的 IDRI 如何产生如此巨大的影响。
